医学
哌加他尼
血管抑制剂
黄斑变性
阿柏西普
血管内皮生长因子
脉络膜新生血管
贝伐单抗
药理学
玻璃体内给药
新生血管
血管内皮生长因子受体
眼科
视网膜
血管生成
内科学
化疗
作者
Francesco Semeraro,Francesco Morescalchi,Sarah Duse,Elena Gambicorti,Anna Cancarini,Ciro Costagliola
出处
期刊:Current Drug Metabolism
[Bentham Science]
日期:2015-10-28
卷期号:16 (7): 572-584
被引量:40
标识
DOI:10.2174/1389200216666151001120831
摘要
Subretinal neovascularization and pathologic ocular angiogenesis are common causes of progressive, irreversible impairment of central vision, and dramatically affect quality of life. Anti-vascular endothelial growth factor (anti-VEGF) therapy has improved the quality of life for many patients with age-related macular degeneration, diabetic retinopathy, and other ocular diseases involving neovascularization and edema. In these pathologies, the inhibition of intraocular VEGF is the only therapy that can preserve vision. Four anti-VEGF drugs are currently used to treat ocular neovascularization; pegaptanib, ranibizumab, and aflibercept have been approved for this condition, while bevacizumab can be used off-label. Anti-VEGF therapy is administered regularly for many months or years because its suspension or discontinuation may cause recurrence of neovascularization. On the other hand, VEGF is necessary for the survival of retinal and choroidal endothelial cells. Experimental studies in animal models have shown that local inhibition of VEGF causes thinning and atrophy of the choriocapillaris and degeneration of photoreceptors, primarily cones. These studies combined with clinical experience indicated that prolonged VEGF inhibition could impair retinal function. Moreover, anti-VEGF compounds can cross the blood-retina barrier, enter the systemic circulation, and inhibit serum VEGF. Since circulating VEGF protects blood vessel integrity, prolonged anti-VEGF treatment could induce thromboembolic adverse events from vascular causes such as heart attack and stroke, and even death. The ocular dosing regimen and systemic toxicity of anti-VEGF compounds are therefore central concerns. A better understanding of this topic requires knowledge of the metabolism, tissue distribution, and clearance of anti-VEGF compounds. This manuscript reviews the properties of anti-VEGF compounds following intravitreal administration.
科研通智能强力驱动
Strongly Powered by AbleSci AI